Mesenteric Fibrosis in Neuroendocrine Neoplasms: a Systematic Review of New Thoughts on Causation and Potential Treatments.

IF 5 2区医学 Q1 ONCOLOGY

Current Oncology Reports Pub Date : 2025-05-01 Epub Date: 2025-04-11 DOI:10.1007/s11912-025-01668-0

Ariadni Spyroglou, Odysseas Violetis, Konstantinos Iliakopoulos, Antonios Vezakis, Krystallenia Alexandraki

{"title":"Mesenteric Fibrosis in Neuroendocrine Neoplasms: a Systematic Review of New Thoughts on Causation and Potential Treatments.","authors":"Ariadni Spyroglou, Odysseas Violetis, Konstantinos Iliakopoulos, Antonios Vezakis, Krystallenia Alexandraki","doi":"10.1007/s11912-025-01668-0","DOIUrl":null,"url":null,"abstract":"Purpose of review: Mesenteric fibrosis (MF) is a hallmark of small intestinal neuroendocrine neoplasms (SI-NEN) and is frequently associated with significant morbidity due to related complications such as intestinal obstruction, ischemia, and cachexia.Recent findings: Herein we performed a systematic review to discuss the development of MF in SI-NEN. The pathophysiological mechanisms acknowledged as causative for the development of MF include the major components of the tumor microenvironment, such as fibroblasts, endothelial and immune cells and the extracellular matrix, which are involved in a complex interplay activating several signaling pathways that promote profibrotic factors and induce both a desmoplastic reaction and tumor proliferation. Surgery remains the mainstay of treatment, while several medical management options of MF complicating SI-NEN available present rather limited efficacy. MF is a frequent characteristic of SI-NEN that requires particular attention and targeted management to avoid complications.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"642-655"},"PeriodicalIF":5.0000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12081589/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Oncology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11912-025-01668-0","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/11 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Mesenteric fibrosis (MF) is a hallmark of small intestinal neuroendocrine neoplasms (SI-NEN) and is frequently associated with significant morbidity due to related complications such as intestinal obstruction, ischemia, and cachexia.

Recent findings: Herein we performed a systematic review to discuss the development of MF in SI-NEN. The pathophysiological mechanisms acknowledged as causative for the development of MF include the major components of the tumor microenvironment, such as fibroblasts, endothelial and immune cells and the extracellular matrix, which are involved in a complex interplay activating several signaling pathways that promote profibrotic factors and induce both a desmoplastic reaction and tumor proliferation. Surgery remains the mainstay of treatment, while several medical management options of MF complicating SI-NEN available present rather limited efficacy. MF is a frequent characteristic of SI-NEN that requires particular attention and targeted management to avoid complications.

查看原文本刊更多论文

神经内分泌肿瘤的肠系膜纤维化：病因和潜在治疗新思路的系统综述。

回顾目的：肠系膜纤维化（MF）是小肠神经内分泌肿瘤（SI-NEN）的一个标志，并且由于肠梗阻、缺血和恶病质等相关并发症而经常与显著的发病率相关。最近的发现：在这里，我们进行了系统的回顾，讨论了MF在SI-NEN中的发展。被认为是MF发展的病理生理机制包括肿瘤微环境的主要组成部分，如成纤维细胞、内皮细胞和免疫细胞以及细胞外基质，它们参与了一个复杂的相互作用，激活了几种促进促纤维化因子的信号通路，诱导了结缔组织增生反应和肿瘤增殖。手术仍然是主要的治疗方法，而MF合并SI-NEN的几种医疗管理选择目前的疗效相当有限。MF是SI-NEN的常见特征，需要特别注意和有针对性的管理，以避免并发症。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Oncology Reports ONCOLOGY-

CiteScore

8.50

自引率

0.00%

发文量

187

审稿时长

6-12 weeks

期刊介绍： This journal aims to review the most important, recently published clinical findings in the field of oncology. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care of those affected by cancer. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as cancer prevention, leukemia, melanoma, neuro-oncology, and palliative medicine. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.